SCYX · Scynexis Inc

-

Please sign in to comment on SCYX

1 Comment

Admin

4 years, 11 months ago

SCYNEXIS, Inc is currently in a long term uptrend where the price is trading 0.5% above its 200 day moving average.

From a valuation standpoint, the stock is 21.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1049.2.

SCYNEXIS, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 111.4% to $909K since the same quarter in the previous year.

Finally, its free cash flow grew by 5.1% to $-10M since the same quarter in the previous year.

Based on the above factors, SCYNEXIS, Inc gets an overall score of 4/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US8112922005
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Market Cap	40M
PE Ratio	None
Target Price	3.4733
Beta	1.32
Dividend Yield	None

ABOUT

Scynexis Inc

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX · Scynexis Inc

-

Scynexis Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Scynexis Inc using a moving average strategy